Loading page content…
Loading page content…
Loading contract search results…
Loading contract details…
| Source: | Find a Tender Service (FTS) |
| Notice Type: | Award notice |
| Buyer: | Barts Health NHS Trust |
| Main Category: | Services |
| Procurement Method: | Direct award |
| Method Rationale: | CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a new personalised immunotherapy treatment where a patient’s T cells are genetically modified to target cancer cells. The products can only be supplied by the the proposed contractor, Bristol Myers Squibb. |
Awarded to
| Award value: | £2,100,000 |
| Award status: | Pending |
CAR-T therapy (Chimeric Antigen Receptor T-cell therapy) is a new personalised immunotherapy treatment where a patient’s T cells are genetically modified to target cancer cells. The proposed contractor, Bristol Myers Squibb, will supply privately developed CAR T products At the time of writing it is only offered at 8 sites across the UK. The proposed contract is for 5 years with the option to extend by up to a further 5 years. The contract does not commit the Trust to place a minimum or any Order. The price paid to the supplier with be capped at NICE / NHS England approved list prices.
Published contracts in the last 12 months
31
total contracts
£145.8m
total value
£8,098,444
average contract size
Typical categories
Pipeline status
Not addedImports the contract into your BidWriter pipeline · Qualify before you commit to bid
Need help writing this bid?
Our specialists write winning tender responses. Free consultation, no obligation.
Book a free consultation →| Tender Status: | Closed |
| Estimated Value (ex. VAT): | Not specified |
| Release Date: | 26 November 2025 |
| Application Deadline: | — |
| Contract Start Date: | — |
| Contract End Date: | 5 December 2030 |
| Contract Duration: | NaN years |
| Procurement ID (OCID): | ocds-h6vhtk-05e8d3 |
| Notice Reference: | 077086-2025 |
View Original Notice
Access the full notice on the official portal